GLP-1 and GIP dual-receptor agonist pharmaceutical composition and application thereof

CN118973603APending Publication Date: 2024-11-15BRIGHTGENE BIO MEDICAL TECHNOLOGY CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202380031541.8
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-09-23
Filing Date
2023-09-21
Publication Date
2024-11-15

AI Technical Summary

Technical Problem

Existing GLP-1 and GIP dual receptor agonist drugs are difficult to store for a long time and have poor efficacy and stability. Polypeptide drugs are prone to polymerization and microbial degradation, leading to drug failure and increased safety risks.

Method used

By adding a stabilizer such as propylene glycol and a buffer salt such as disodium hydrogen phosphate dodecahydrate, the pH value of the pharmaceutical composition is controlled within the range of 6.5 to 8.5 to avoid drug polymerization and degradation, and prepare a bacteriostatic-free liquid preparation.

Benefits of technology

It achieves long-term storage and biological activity maintenance of GLP-1 and GIP dual receptor agonists, reduces the risk of drug aggregation and degradation, improves the stability and safety of the drug, and is suitable for the treatment of diabetes and obesity.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118973603A_ABST
    Figure CN118973603A_ABST
Patent Text Reader

Abstract

The invention provides a GLP-1 and GIP dual-receptor stimulant pharmaceutical composition. The GLP-1 and GIP dual-receptor stimulant pharmaceutical composition comprises a GLP-1 and GIP dual-receptor stimulant, a stabilizer and a buffer salt. The invention also provides application of the pharmaceutical composition in preparation of medicines for preventing and / or treating metabolic disorder related diseases.
Need to check novelty before this filing date? Find Prior Art

Description

A GLP-1 and GIP dual receptor agonist pharmaceutical composition and its use

[0001] This disclosure claims priority to the following patent application: Chinese patent application filed with the China Patent Office on September 23, 2022, with application number 202211167785.2; the entire contents of the above patent application are incorporated into this disclosure by reference. Technical Field

[0002] The present disclosure belongs to the field of medicine, and specifically relates to a GLP-1 and GIP dual receptor agonist pharmaceutical composition and its use. Background Art

[0003] Glucose-dependent insulinotropic peptide (GIP) is a 42-amino acid gastrointestinal regulatory peptide that plays a physiological role in glucose homeostasis by stimulating insulin secretion from pancreatic β cells in the presence of glucose and protecting pancreatic β cells. Glucagon-like peptide-1 (GLP-1) is a 37-amino acid peptide that stimulates insulin secretion, protects pancreatic β cells, and inhibits glucagon secretion, gastric emptying, and food intake, leading to weight loss. GIP and GLP-1 are secreted by K cells and L cells of the small intestinal endothelium, respectively, and are known as incretins. Incretin receptor signaling plays a key physiological role in glucose homeostasis.

[0004] Both GIP and GLP-1 produce their corresponding physiological effects by binding to their specific receptors, namely the GIP (GIPR) receptor and the GLP-1 receptor (GLP-1R), respectively. Studies have shown that co-stimulation of the GLP-1R / GIPR can exert a synergistic hypoglycemic effect, and dual agonists of GIP and GLP-1 receptors may produce even more superior blood sugar-lowering effects and stimulate insulin secretion. Therefore, the development of novel and effective GLP-1 and GIP dual receptor agonists and pharmaceutical compositions thereof has been a research hotspot in the treatment of metabolic diseases such as diabetes and obesity.

[0005] At present, polypeptide drugs are mostly stored and used in the form of liquid preparations. The active ingredients of polypeptides are easily affected by the external environment, resulting in chemical changes such as hydrolysis and oxidation. The impurities produced will seriously affect the effectiveness and safety of the drugs.

[0006] GLP-1 and GIP dual receptor agonists are generally linear peptides, and because the pH of the preparation needs to be close to the physiological pH of the human body, the pH value of the preparation is generally controlled at around 7-8. Peptide drugs are extremely susceptible to microbial degradation under these pH conditions, and in general, antibacterial agents (such as phenol) are considered to be added to the prescription to improve the stability of the product. For example, 8.25 mg of phenol is added as an antibacterial agent to the commercially available antidiabetic drug semaglutide (OZEMPIC); 2.64 mg of meta-cresol is added to exenatide as an antibacterial agent, 16.5 mg of phenol is added to liraglutide (VICTOZA) as an antibacterial agent, and 8.1 mg of meta-cresol is added to lixisenatide (ADLYXIN) as an antibacterial agent. However, injections enter the human body's circulation directly, and the use of antibacterial agents will increase drug safety risks. Currently, national regulatory agencies have also issued many documents, and the use of preservatives should be minimized when screening prescriptions for insulin products. Therefore, developing a prescription without antibacterial agents in polypeptide hypoglycemic drugs is also a technical challenge in this field. The development of GLP-1 and GIP dual receptor agonist preparations without preservatives / antibacterial agents will have good application prospects.

[0007] Furthermore, peptide drugs are composed of multiple amino acids linked by amide bonds formed through condensation reactions. Due to their abundance of electron-rich and electron-withdrawing groups, peptide drugs are prone to intermolecular attraction during formulation, leading to drug aggregation. Once aggregated, peptide drugs lose their efficacy. Furthermore, drug aggregation can also cause turbidity or discoloration in the injection. Therefore, addressing the issue of drug aggregation during the preparation of peptide drugs has long been a technical challenge in this field.

[0008] In summary, developing a pharmaceutical composition formula of GLP-1 and GIP dual receptor agonists that is suitable for long-term storage and has stable efficacy is an urgent problem to be solved in this field.

[0009] Summary of the Invention

[0010] Problems to be solved by the invention

[0011] In order to develop a GLP-1 and GIP dual receptor agonist with a novel structure that can effectively treat obesity, diabetes and its complications, the applicant of this application provides a GLP-1 and GIP dual receptor agonist in the patent application with application number 202210294984.3 and invention name "GIP and GLP-1 dual receptor agonist, pharmaceutical composition and use". This dual receptor agonist is a glucose-dependent incretin peptide GLP-1 and GIP dual receptor agonist independently developed by the applicant of this application, and its intended clinical indication is type 2 diabetes. This drug is a linear peptide containing 40 amino acids that has the effect of stimulating GLP-1R and GIPR. Preclinical studies have shown that this dual receptor agonist has a strong stimulatory effect on both GLP-1 and GIP receptors, and its activity is 2 to 3 times stronger than that of Tirzepatide; the side chain is composed of a fatty acid chain connected by a double AEEEA chain. The main function of the side chain is to bind to albumin in the blood (albumin has basic residues), prolonging the half-life and achieving long-term effect. The results of preclinical pharmacokinetic studies showed that the binding rate of this dual receptor agonist to various plasma proteins exceeded 99.4%, and its half-life in rats and crab-eating monkeys was approximately 14 hours and 40 hours, respectively.

[0012] However, there are currently no pharmaceutical formulations suitable for long-term storage and stable efficacy of the aforementioned GLP-1 and GIP dual receptor agonists. To address this, the present disclosure provides a pharmaceutical composition of a GLP-1 and GIP dual receptor agonist and its uses. By adding excipients such as stabilizers and buffer salts, the GLP-1 and GIP dual receptor agonist is stabilized in a liquid formulation, effectively preventing physical and chemical degradation.

[0013] Solutions for solving problems

[0014] In a first aspect, the present disclosure provides a pharmaceutical composition comprising a GLP-1 and GIP dual receptor agonist, a stabilizer, and a buffer salt; the GLP-1 and GIP dual receptor agonist is a compound as shown in Formula I, or a pharmaceutically acceptable salt, ester, solvate, optical isomer, tautomer, isotope-labeled, or prodrug thereof:

[0015] Furthermore, the pharmaceutical composition is a liquid preparation; preferably, the pharmaceutical composition is an injection.

[0016] Furthermore, the concentration of the GLP-1 and GIP dual receptor agonist in the pharmaceutical composition is 2 to 36 mg / mL, preferably 5 to 30 mg / mL.

[0017] Furthermore, in the pharmaceutical composition, the stabilizer is a polyol; preferably, the stabilizer is propylene glycol, mannitol or glycerol; more preferably, the stabilizer is propylene glycol.

[0018] Furthermore, the concentration of the stabilizer in the pharmaceutical composition is 10 to 20 mg / mL.

[0019] Furthermore, in the pharmaceutical composition, the buffer salt is selected from hydrogen phosphate, hydrogen phosphate hydrate, citrate or citrate hydrate; preferably, the buffer salt is disodium hydrogen phosphate dodecahydrate or sodium citrate dihydrate; more preferably, the buffer salt is disodium hydrogen phosphate dodecahydrate.

[0020] Furthermore, the concentration of the buffer salt in the pharmaceutical composition is 7-23 mM.

[0021] Furthermore, the pH value of the pharmaceutical composition is 6.5 to 8.5; preferably, the pH value of the pharmaceutical composition is 7.0 to 8.4; preferably, the pH value of the pharmaceutical composition is 7.2 to 8.2; more preferably, the pH value of the pharmaceutical composition is 7.2 to 7.6.

[0022] Furthermore, the pharmaceutical composition also contains a pH regulator and water; the pH regulator is hydrochloric acid and / or sodium hydroxide; the pH value of the pharmaceutical composition is adjusted by the pH regulator; and the water is preferably purified water and / or water for injection.

[0023] Furthermore, the pharmaceutical composition does not contain an antibacterial agent.

[0024] A second aspect of the present invention provides a pharmaceutical composition comprising a GLP-1 and GIP dual receptor agonist represented by Formula I, a stabilizer, and a buffer salt, wherein the stabilizer is propylene glycol, the buffer salt is disodium hydrogen phosphate dodecahydrate, and the pH value of the pharmaceutical composition is 7.0 to 8.4; and in the pharmaceutical composition, the concentration of the GLP-1 and GIP dual receptor agonist represented by Formula I is 5 to 30 mg / mL, the concentration of the propylene glycol is 10 to 20 mg / mL, and the concentration of the disodium hydrogen phosphate dodecahydrate is 7 to 23 mM;

[0025] The pharmaceutical composition is an injection.

[0026] Furthermore, the pH value of the pharmaceutical composition is 7.2-8.2, and the concentration of disodium hydrogen phosphate dodecahydrate in the pharmaceutical composition is 10-20 mM.

[0027] Furthermore, the pH value of the pharmaceutical composition is 7.2-7.6; in the pharmaceutical composition, the concentration of the GLP-1 and GIP dual receptor agonist represented by Formula I is 5-25 mg / mL, the concentration of the propylene glycol is 14 mg / mL, and the concentration of the sodium hydrogen phosphate dodecahydrate is 10 mM.

[0028] Furthermore, the pharmaceutical composition further comprises a pH regulator and water; preferably, the pH regulator is hydrochloric acid and / or sodium hydroxide; preferably, the water is purified water and / or water for injection.

[0029] The third aspect of the present disclosure provides a method for preparing the pharmaceutical composition described in the first aspect or the second aspect, which comprises the following steps: preparing a stabilizer, a buffer salt and a GLP-1 and GIP dual receptor agonist into a solution, and adjusting the pH value of the solution to a target value.

[0030] Furthermore, the preparation method includes the following steps: dissolving a stabilizer and a buffer salt in a solvent, adding a GLP-1 and GIP dual receptor agonist to prepare a solution, adding a pH adjuster to completely dissolve the GLP-1 and GIP dual receptor agonist, and then using the pH adjuster to adjust the pH value of the solution to a target value.

[0031] The fourth aspect of the present disclosure provides use of the pharmaceutical composition described in the first aspect or the second aspect in the preparation of a medicament for preventing and / or treating metabolic disorder-related diseases; preferably, the metabolic disorder-related diseases are diabetes, diabetic complications, obesity or obesity complications.

[0032] Effects of the Invention

[0033] The present disclosure provides a pharmaceutical composition in which excipients such as stabilizers and buffer salts are added to maintain good stability of the GLP-1 and GIP dual receptor agonists, which are the active pharmaceutical ingredients, in a liquid preparation. This avoids quality issues such as drug failure caused by polymerization between the GLP-1 and GIP dual receptor agonists, which are polypeptide drugs. Ultimately, the long-term preservation of the pharmaceutical composition is achieved, showing important application prospects in the prevention and treatment of metabolic disorder-related diseases such as diabetes or diabetic complications, and obesity or obesity complications.

[0034] The present disclosure utilizes a pH regulator to control the pH value of the pharmaceutical composition within a specific range, which is more conducive to the complete dissolution of the GLP-1 and GIP dual receptor agonists during the preparation process of the pharmaceutical composition, and ensures the stability of the GLP-1 and GIP dual receptor agonists as the active pharmaceutical ingredients of the composition during storage, thereby preventing degradation.

[0035] The present disclosure greatly improves the solubility of the GLP-1 and GIP dual receptor agonist (such as the compound of formula I) by selecting a specific stabilizer, while ensuring that the compound has an intact structure and biological activity during storage.

[0036] The present disclosure can ensure the stability of the pH value of the pharmaceutical composition during storage by selecting a specific buffer salt without affecting the quality and stability of the active ingredients of the pharmaceutical composition.

[0037] The preparation method of the pharmaceutical composition provided by the present disclosure is simple to operate, has low production cost, is conducive to large-scale production, and provides assistance for the large-scale application of pharmaceutical preparations.

[0038] The pharmaceutical composition provided by the present disclosure can effectively prevent and / or treat metabolic disorder-related diseases such as diabetes, diabetic complications, obesity or obesity complications, and the method of use is convenient. BRIEF DESCRIPTION OF THE DRAWINGS

[0039] Figure 1 is a specificity map for validating the multimer detection method.

[0040] Figure 2 is a multimer detection spectrum of the injection of the compound of formula I. DETAILED DESCRIPTION

[0041] <Definition>

[0042] Unless stated otherwise, the terms used in this disclosure have the following meanings.

[0043] In the claims and / or description of the present invention, the word "a" or "an" or "the" may mean "one", but may also mean "one or more", "at least one" and "one or more than one".

[0044] As used in the claims and the specification, the words "comprising," "having," "including," or "containing" are inclusive or open-ended and do not exclude additional, unrecited elements or method steps. At the same time, "comprising," "having," "including," or "containing" can also be closed-ended and exclude additional, unrecited elements or method steps.

[0045] In this disclosure, the term "about" means that a value includes the standard deviation of error for the device or method being employed to determine the value.

[0046] In this disclosure, the term "agonist" refers to a substance (ligand) that activates signaling through the target receptor type. For example, if the GLP-1 receptor is the target receptor, the agonist has GLP-1 receptor activating activity, such as a GLP-1 polypeptide or an analog thereof.

[0047] In the present disclosure, the term "treatment" means that after a subject has contracted a disease, the subject is exposed to (e.g., administered) the pharmaceutical composition of the present disclosure, thereby alleviating the symptoms of the disease compared to when the subject had not contracted the disease. It does not necessarily mean that the symptoms of the disease are completely suppressed. Suffering from a disease means that the body has symptoms of the disease.

[0048] In the present disclosure, the term "prevention" means that before a subject develops a disease, the subject is exposed to (e.g., administered) the pharmaceutical composition of the present disclosure, thereby reducing the symptoms after developing the disease compared to when the subject does not develop the disease. It does not necessarily mean that the disease must be completely suppressed.

[0049] In the present disclosure, the terms "individual," "patient," or "subject" include mammals. Mammals include, but are not limited to, domestic animals (e.g., cows, sheep, cats, dogs, and horses), primates (e.g., humans and non-human primates such as monkeys), rabbits, and rodents (e.g., mice and rats).

[0050] In the present disclosure, the term "therapeutically effective amount" refers to an amount effective to achieve the desired therapeutic outcome at the required dosage and for the required period of time. The therapeutically effective amount of a compound or pharmaceutical composition of the present disclosure can vary depending on a variety of factors such as the disease state, the age, sex, and weight of the individual, and the ability of the immunoadjuvant or pharmaceutical composition to elicit a desired response in the individual.

[0051] In the present disclosure, the term "pharmaceutically acceptable salt" refers to a salt prepared from a compound of the present disclosure with a relatively non-toxic acid or base. When the compound of the present disclosure contains a relatively acidic functional group (e.g., a carboxyl group or a sulfonic acid group), a base addition salt can be obtained by contacting its free form with a sufficient amount of a base in a pure solution or a suitable inert solvent. Non-limiting examples of pharmaceutically acceptable base addition salts include, but are not limited to, sodium salts, potassium salts, ammonium salts, calcium salts, magnesium salts, organic amine salts, or similar salts. When the compound of the present disclosure contains a relatively alkaline functional group (e.g., an amino group or a guanidine group), an acid addition salt can be obtained by contacting its free form with a sufficient amount of an acid in a pure solution or a suitable inert solvent. Non-limiting examples of pharmaceutically acceptable acid addition salts include, but are not limited to, inorganic acid salts (e.g., hydrochloride, hydrobromide, hydroiodide, nitrate, carbonate, bicarbonate, phosphate, monohydrogen phosphate, dihydrogen phosphate, phosphite, sulfate, bisulfate, etc.), organic acid salts (e.g., acetate, propionate, isobutyrate, malonate, succinate, suberate, maleate, fumarate, citrate, tartrate, lactate, mandelate, benzoate, phthalate, methanesulfonate, benzenesulfonate, p-toluenesulfonate, glucuronic acid, etc.), and amino acid salts (e.g., arginine salt, etc.). Specific forms of pharmaceutically acceptable salts can also be found in Berge et al., "Pharmaceutical Salts", Journal of Pharmaceutical Science, 1977, 66: 1-19).

[0052] In the present disclosure, the term "metabolic disorder" may be a glucose metabolism disorder disease such as diabetes, diabetic complications, obesity, obesity complications, etc. Since the associations between obesity, diabetes and blood glucose metabolism are well-known, these conditions may but do not have to be separate or mutually exclusive. In some embodiments, diabetes or diabetic complications include insulin resistance, glucose intolerance, elevated fasting blood glucose, prediabetes, type I diabetes, type II diabetes, gestational diabetes hypertension, dyslipidemia or a combination thereof. In some embodiments, obesity complications include obesity-associated inflammation, obesity-associated gallbladder disease or obesity-induced sleep apnea, or may be selected from the following related conditions: atherogenic dyslipidemia, dyslipidemia, elevated blood pressure, hypertension, prethrombotic state and proinflammatory state or a combination thereof.

[0053] The pharmaceutical composition of the present disclosure has excellent dual agonist activity for GIPR and GLP-1R, can effectively reduce blood glucose and control the body weight gain of type II diabetic model mice, and is used for preventing and / or treating metabolic disorder diseases, having good clinical applications and pharmaceutical uses.

[0054] <GLP-1 and GIP Dual Receptor Agonist>

[0055] In the present disclosure, the GLP-1 and GIP dual receptor agonist refers to a substance that targets the GLP-1 receptor and the GIP receptor and has activation activity for both GLP-1R and GIPR simultaneously.

[0056] In some specific embodiments, the GLP-1 and GIP dual receptor agonist described in the present disclosure is a compound represented by Formula I or a pharmaceutically acceptable salt, ester, solvate, optical isomer, tautomer, isotope-labeled substance or prodrug thereof:

[0057] The present disclosure does not particularly limit the content of the drug active ingredient in the pharmaceutical composition, which can be determined by those skilled in the art according to actual needs.

[0058] In some embodiments, the concentration of the GLP-1 and GIP dual receptor agonist described in the present disclosure is 2 to 36 mg / mL; for example, 2 mg / mL, 3 mg / mL, 4 mg / mL, 5 mg / mL, 6 mg / mL, 7 mg / mL, 8 mg / mL, 9 mg / mL, 10 mg / mL, 11 mg / mL, 12 mg / mL, 13 mg / mL, 14 mg / mL, 15 mg / mL, 16 mg / mL, 17 mg / mL, 18 mg / mL, 19 mg / mL, 20 mg / mL, 21 mg / mL, 22 mg / mL, 23 mg / mL, 24 mg / mL, 25 mg / mL, 26 mg / mL, 27 mg / mL, 28 mg / mL, 29 mg / mL, 30 mg / mL, 31 mg / mL, 32 mg / mL, 33 mg / mL, 34 mg / mL, 35 mg / mL, 36 mg / mL, etc.; preferably, 5 to 30 mg / mL.

[0059] <Stabilizer>

[0060] In this disclosure, stabilizers refer to substances used to stabilize the structure and biological activity of polypeptides in solution. Particularly for polypeptide formulations, screening for suitable stabilizers is a primary means of preventing physical and chemical degradation of polypeptide drug molecules in liquid formulations. Selecting an appropriate stabilizer can improve the stability of polypeptide molecules by binding to their hydrophobic moieties, increasing the viscosity of the solution, and influencing their folding state.

[0061] The present disclosure does not particularly limit the specific type of stabilizer, which can be determined by those skilled in the art according to actual needs.

[0062] In some embodiments, the stabilizers described in the present disclosure are selected from polyols.

[0063] In some specific embodiments, the stabilizer described in the present disclosure is propylene glycol, mannitol or glycerol.

[0064] Based on the results of the prescription screening test and the results of the stability test, the present disclosure preferentially selects propylene glycol as a stabilizer, which can effectively maintain the structure and biological activity of the main drug and can also stabilize the pH value of the pharmaceutical composition during storage.

[0065] The present disclosure does not particularly limit the amount of the stabilizer, and can be determined by those skilled in the art according to actual needs.

[0066] In some embodiments, the concentration of the stabilizer described in the present disclosure is 10 to 20 mg / mL; for example, 10 mg / mL, 11 mg / mL, 12 mg / mL, 13 mg / mL, 14 mg / mL, 15 mg / mL, 16 mg / mL, 17 mg / mL, 18 mg / mL, 19 mg / mL, 20 mg / mL, etc.; preferably 14 mg / mL.

[0067] It is worth mentioning that in polypeptide preparations, sodium chloride is considered to maintain electrolyte balance and stabilize the polypeptide structure, and it exists as a stabilizer in many existing polypeptide preparations. However, when the inventors of the present disclosure replaced propylene glycol with sodium chloride (for example, a 2 mL pharmaceutical composition contains 40.0 mg of Compound I, 3.58 mg of disodium hydrogen phosphate dodecahydrate, 16.4 mg of sodium chloride, and the pH value is adjusted to 7 with a pH regulator and then the volume is made up with water for injection), the solubility of Compound I is only 0.15 mg / mL, far from meeting the requirements. When propylene glycol is used as a stabilizer (for example, a 1 mL pharmaceutical composition contains 20.0 mg of Compound I, 3.58 mg of disodium hydrogen phosphate dodecahydrate, 14 mg of propylene glycol, and the pH value is adjusted to 7 with a pH regulator and then the volume is made up with water for injection), the solubility of Compound I can reach more than 30 mg / mL, meeting the solubility requirements of the main drug. Therefore, in some preferred embodiments of the present disclosure, the pharmaceutical composition does not contain sodium chloride.

[0068] <pH value and pH regulator>

[0069] The pH value has a great influence on the stability of the polypeptide drugs GLP-1 and GIP dual receptor agonists. At the same time, it also affects the dissolution of the main drug during the preparation process of the pharmaceutical composition. An acidic environment is not conducive to the dissolution of the GLP-1 and GIP dual receptor agonists provided in the present disclosure. As the pH increases, the purity decreases faster during the storage of the product, indicating that a slightly alkaline condition is not conducive to the stability of the product.

[0070] In some embodiments, the pH value of the pharmaceutical composition of the present disclosure is 6.5 to 8.5; for example, 6.5, 6.6, 6.7, 6.8, 6.9, 7.0, 7.1, 7.2, 7.3, 7.4, 7.5, 7.�, 7.7, 7.8, 7.9, 8.0, 8.1, 8.2, 8.3, 8.4, 8.5, etc.; preferably 7.0 to 8.4; more preferably 7.2 to 8.2; further preferably 7.2 to 7.6.

[0071] A reasonable pH value range not only ensures the purity and stability of the pharmaceutical composition of the present disclosure during storage, but also takes into account the pH fluctuations during drug storage, thus ensuring the stability of the pharmaceutical composition throughout the process from production to use.

[0072] In some embodiments, the present disclosure utilizes a pH adjusting agent to adjust the pH of a pharmaceutical composition.

[0073] In some specific embodiments, the pH adjuster described herein is hydrochloric acid and / or sodium hydroxide. Hydrochloric acid is a transparent, colorless, fuming hydrochloric acid solution with a pungent odor and is commonly used as an acidifier in pharmaceutical formulations. Sodium hydroxide is a molten, white, dry granules, blocks, rods, or flakes that is generally considered non-toxic at low concentrations and is widely used in pharmaceutical formulations to adjust the pH of solutions. In some more specific embodiments, the pH adjuster described herein can be a certain concentration of hydrochloric acid and / or a certain concentration of sodium hydroxide solution.

[0074] The present disclosure does not limit the concentration of the pH adjuster, and those skilled in the art can adjust it according to actual production needs. For example, a lower concentration of pH adjuster, such as a concentration below 3M, or a higher concentration of pH adjuster, such as a concentration above 3M, can be selected, both of which have no adverse effects on the active pharmaceutical ingredient. The present disclosure preferably uses 0.1M hydrochloric acid and / or 0.1M sodium hydroxide solution.

[0075] <Buffer Salt>

[0076] In this disclosure, buffer salts refer to substances used to stabilize the pH of a solution. Particularly for peptide formulations, selecting an appropriate buffer salt system is an important means of preventing physical and chemical degradation of peptide drug molecules in liquid formulations. Selecting an appropriate buffer salt system can improve peptide stability by maintaining a stable pH value in the peptide solution and influencing electrostatic interactions.

[0077] The present disclosure does not particularly limit the specific type of buffer salt, which can be determined by those skilled in the art according to actual needs.

[0078] In some embodiments, the buffer salt of the present disclosure is selected from hydrogen phosphate, hydrogen phosphate hydrate, citrate, or citrate hydrate.

[0079] In some specific embodiments, the buffer salt described in the present disclosure is disodium hydrogen phosphate dodecahydrate or sodium citrate dihydrate.

[0080] In some preferred embodiments, the buffer salt disclosed herein is disodium hydrogen phosphate dodecahydrate, which not only helps stabilize the pH value of the pharmaceutical composition disclosed herein during storage, but also helps stabilize the purity of the pharmaceutical composition during storage.

[0081] Based on the results of the prescription screening test and combined with the stability test data, the present disclosure preferentially selects disodium hydrogen phosphate dodecahydrate as the buffer salt, which has stable chemical properties, does not affect the quality and stability of the main drug, and has a good effect in maintaining the stability of the pH value of the preparation.

[0082] The present disclosure does not particularly limit the amount of the buffer salt, and it can be determined by those skilled in the art according to actual needs.

[0083] In some embodiments, the buffer salt concentration described in the present disclosure is 7-23 mM; for example, 7 mM, 8 mM, 9 mM, 10 mM, 11 mM, 12 mM, 13 mM, 14 mM, 15 mM, 16 mM, 17 mM, 18 mM, 19 mM, 20 mM, 21 mM, 22 mM, 23 mM, etc.; preferably 7-20 mM; more preferably 7-15 mM.

[0084] Based on the results of the prescription screening test and taking into account the risk level of the pharmaceutical composition as an injection preparation in subsequent clinical applications, the present disclosure gives priority to low-concentration buffer salts, such as 10 mM concentration.

[0085] <Bacteriostatic Agents>

[0086] The GLP-1 and GIP dual receptor agonist disclosed in the present invention is a linear peptide containing 40 amino acids, and the pH value of the preparation is initially set between 7.2 and 8.2. It is easily degraded by microorganisms. Generally, it is considered to add an antibacterial agent (such as phenol) to the prescription to improve the stability of the product.

[0087] Moreover, since polypeptide drugs are easily degraded by microorganisms, adding antibacterial agents to polypeptide hypoglycemic drugs is a common technical means in this field. For example, 8.25 mg of phenol is added as an antibacterial agent to the commercially available hypoglycemic drug product semaglutide (OZEMPIC); 2.64 mg of meta-cresol is added as an antibacterial agent to exenatide, 16.5 mg of phenol is added as an antibacterial agent to liraglutide (VICTOZA), and 8.1 mg of meta-cresol is added as an antibacterial agent to lixisenatide (ADLYXIN).

[0088] However, after long-term exploration and research, the inventors of the present disclosure found that the safety of clinical medication can be guaranteed without adding antibacterial agents, and the risk factors of the pharmaceutical composition during application can be further reduced.

[0089] In the absence of antibacterial agents in the composition, it is more conducive to controlling or reducing the risks of the drug preparation in clinical use, and to a certain extent reduces the production cost of the drug composition, which is more conducive to large-scale production and application of the drug.

[0090] <Pharmaceutical Composition>

[0091] The pharmaceutical composition of the present disclosure comprises a GLP-1 and GIP dual receptor agonist, a stabilizer, and a buffer salt.

[0092] In some embodiments, the pharmaceutical compositions described herein further comprise a pH adjuster and a solvent.

[0093] In some specific embodiments, the pharmaceutical composition described in the present disclosure consists of a GLP-1 and GIP dual receptor agonist, a stabilizer, a buffer salt, a pH adjuster, and a solvent.

[0094] The pharmaceutical composition provided by the present disclosure exhibits a good activation effect on GLP-1R and GIPR in vivo. The description of each component in the pharmaceutical composition is as described above.

[0095] In some embodiments, the pharmaceutical compositions of the present disclosure are liquid formulations.

[0096] In some specific embodiments, the pharmaceutical composition described in the present disclosure is an injection.

[0097] In some more specific embodiments, the solvent used in the liquid formulation of the pharmaceutical composition of the present disclosure is water, preferably purified water or water for injection.

[0098] The present disclosure also provides a method for preparing the pharmaceutical composition, which comprises the following steps: preparing a stabilizer, a buffer salt and a GLP-1 and GIP dual receptor agonist into a solution, and adjusting the pH value of the solution to a target value.

[0099] In some specific embodiments, the preparation method of the pharmaceutical composition includes the following steps: dissolving a stabilizer and a buffer salt in a solvent, adding a GLP-1 and GIP dual receptor agonist, and adding a pH adjuster to completely dissolve the GLP-1 and GIP dual receptor agonist, and then using the pH adjuster to adjust the pH value of the solution to a target value.

[0100] In some more specific embodiments, the preparation method of the pharmaceutical composition comprises the following steps: dissolving a prescribed amount of disodium hydrogen phosphate dodecahydrate and propylene glycol in purified water or water for injection, adding a prescribed amount of a GLP-1 and GIP dual receptor agonist, and adding sodium hydroxide to completely dissolve the GLP-1 and GIP dual receptor agonist, adjusting the pH of the solution to 6.5 to 8.5 using hydrochloric acid and / or sodium hydroxide, and derating to volume with purified water or water for injection. The purpose of adding sodium hydroxide is to appropriately raise the pH of the solution, thereby facilitating the dissolution of the GLP-1 and GIP dual receptor agonist.

[0101] In the present disclosure, the route of administration can be varied or adjusted in any applicable manner to meet the requirements of the nature of the drug, the convenience of the patient and medical staff, and other relevant factors.

[0102] <Medical Use of Pharmaceutical Composition>

[0103] The pharmaceutical composition disclosed herein can be used to prevent and / or treat metabolic disorder-related diseases; preferably, the metabolic disorder-related diseases are diabetes, diabetic complications, obesity or obesity complications.

[0104] The pharmaceutical composition disclosed herein can be further used to prepare drugs for preventing and / or treating metabolic disorder-related diseases; preferably, the metabolic disorder-related diseases are diabetes, diabetic complications, obesity, or obesity complications.

[0105] The present disclosure also provides a method for preventing and / or treating metabolic disorder-related diseases, comprising administering to a subject a preventively and / or therapeutically effective amount of the pharmaceutical composition according to the present disclosure; preferably, the metabolic disorder-related disease is diabetes, diabetic complications, obesity, or obesity complications.

[0106] Example

[0107] In order to make the purpose and technical solutions of the present disclosure clearer, the embodiments of the present disclosure are described in detail below in conjunction with examples. However, those skilled in the art will understand that the following examples are only used to illustrate the present disclosure and should not be regarded as limiting the scope of the present disclosure.

[0108] The reagents and instruments used in the examples are all commercially available products. If no specific conditions are specified, the experiments were carried out according to conventional conditions or those recommended by the manufacturer.

[0109] Example 1: Prescription Screening

[0110] Considering the characteristics of this product as an injection, the concentration and type of buffer salts, the type of stabilizer, and the pH range of the solution in the formulation are screened. The compound of formula I used in the formulation study was prepared by the applicant, and the other materials used were commercially available.

[0111] (1) Screening of stabilizer types

[0112] Stabilizers can improve the stability of peptide formulations by binding to the hydrophobic portion of peptide molecules, increasing solution viscosity, and influencing the folding state of peptide molecules. To screen for suitable stabilizers, formulations were prepared using propylene glycol, mannitol, and glycerol. The prepared samples were subjected to high-temperature and long-term stability tests at 40°C and 2-8°C, respectively. Samples were collected at different time points to test properties, pH, and purity to investigate the effects of different stabilizers on the quality of the drug solution. Prescription information is shown in Table 1, and the results are shown in Table 2.

[0113] Table 1 Prescription information Note: “NA” means not added.

[0114] Table 2 Stabilizer type screening results

[0115] Samples using stabilizers were relatively stable at 2-8°C. After one month, no significant changes were observed in properties, pH, purity, or maximum impurity. After 10 days at 40°C, the purity of the samples decreased, while no significant changes were observed in properties or maximum impurity. However, surprisingly, the formulation stabilized with propylene glycol exhibited a pH change of less than 3% under the conditions of the high-temperature accelerated stabilization test, demonstrating that the propylene glycol formulation achieved unexpected technical results in maintaining pH stability. In contrast, the pH values ​​of the formulations stabilized with mannitol and glycerol exhibited significant changes under the conditions of the high-temperature accelerated stabilization test, decreasing by 0.7-0.8, showing a clear downward trend. Therefore, propylene glycol is the preferred stabilizer for this product.

[0116] (2) pH range screening

[0117] pH is a critical quality attribute of peptide pharmaceutical formulations, directly affecting their solubility, stability, and aggregation. This study focused on the solubility of the API and product stability within a pH range of 5.0 to 8.4. Prescription information is shown in Table 3, and results are shown in Table 4.

[0118] Table 3 Prescription information

[0119] Table 4 Preliminary confirmation results of the pH range of the preparation

[0120] The results showed that at pH values ​​between 5.0 and 6.0, the solubility of the API was insufficient to meet the requirements for the finished drug product. Higher pH values ​​were found to be more conducive to the dissolution of the API. Within the target pH range of 7.4 to 8.4, the purity of the samples decreased significantly with increasing pH under high temperature and accelerated conditions, indicating that alkaline conditions were detrimental to product stability. However, considering the extent of degradation, the reduction in product purity was still acceptable at the target pH of 8.4. All other test items (properties and pH) showed no significant changes.

[0121] (3) Buffer salt concentration screening

[0122] Generally speaking, pH and ionic strength significantly impact the stability and solubility of peptides. Improving the stability and safety of peptide drugs while maintaining their solubility has always been a technical challenge for peptide drug formulations. Appropriate buffer salt concentrations can help address this issue. Therefore, to screen for suitable buffer salt concentrations, sodium citrate dihydrate was used in formulations at concentrations of 10mM, 15mM, and 20mM, respectively. The prepared samples were exposed to temperatures of 40°C and 25°C for high-temperature and long-term evaluations. Specific prescription information is shown in Table 5, and the results are shown in Table 6.

[0123] Table 5 Prescription information

[0124] Table 6 Buffer salt concentration screening results

[0125] The results showed that, among the injection samples prepared at different buffer salt concentrations, only the 10mM buffer salt concentration formulation had a slightly better purity than the 15mM and 20mM buffer salt concentration formulations when stored at 25°C for one month. No significant differences were observed in other parameters, and buffer salt concentrations ranging from 10mM to 20mM met the requirements. However, considering that a higher amount of excipients in an injection leads to greater risks in the clinical application of the preparation, the lowest concentration of 10mM was selected as the buffer salt concentration for the disclosed injection, which further ensures the safety of the preparation.

[0126] (4) Buffer salt system screening

[0127] The choice of buffer system is also crucial for improving formulation stability. To screen for suitable buffer salts, sodium citrate dihydrate and disodium hydrogen phosphate dodecahydrate were used in formulations. The prepared samples were exposed to temperatures of 40°C and 2-8°C, respectively, to assess their performance in high-temperature and long-term studies. Detailed formulation information is shown in Table 7, and the results are shown in Table 8.

[0128] Table 7 Prescription Information Note: “NA” means not added.

[0129] Table 8 Buffer salt system screening results

[0130] The results showed that both disodium hydrogen phosphate dodecahydrate and sodium citrate can be used as buffer salts for the injection disclosed herein. When placed at a high temperature of 40°C for 10 days, the purity of the phosphate formulation was slightly better than that of the citrate formulation. Therefore, disodium hydrogen phosphate dodecahydrate can be preferred as the buffer salt.

[0131] (5) Further confirmation of pH range

[0132] Preliminary confirmation of the pH range indicates that a neutral pH value is beneficial for product stability. Furthermore, for subcutaneous injection, the closer the pH is to physiological, the less irritating the product is. Therefore, a study was designed using disodium hydrogen phosphate dodecahydrate as a buffer salt to investigate a narrower pH range around pH 7.4 to further confirm the optimal pH value for this product. Prescription information is shown in Table 9, and the results are shown in Table 10.

[0133] Table 9 Prescription Information

[0134] Table 10: Further confirmation results of the pH range of the preparation

[0135] Results showed that when the pH value was between 7.2 and 7.6, total impurities and polymers increased slightly after 10 days at 40°C, while properties, pH, maximum single impurity, and RRT of 1.04 remained unchanged. After one month of long-term storage, no significant changes were observed in any of the parameters examined. There were no significant differences between samples at different pH values. Furthermore, the disclosed formulation, without the addition of antibacterial agents, was able to control impurities within a range with no significant changes, achieving unexpected technical benefits.

[0136] In other embodiments of the present disclosure, the concentration of the active pharmaceutical ingredient (API) can also be 5 mg / mL, 10 mg / mL, 15 mg / mL, 25 mg / mL, or 30 mg / mL, while the concentrations of other excipients remain unchanged. It is understood that those skilled in the art can also adjust the API concentration according to the specific conditions of the patient, which is within the scope of the present disclosure.

[0137] In the present disclosure, the purified water in the above prescriptions 1-16 can be replaced with water for injection. The experimental results data obtained by the water for injection prescriptions obtained after the replacement are not significantly different from the experimental results data of the above purified water prescriptions.

[0138] Example 2: Preparation of a GLP-1 and GIP dual receptor agonist pharmaceutical composition

[0139] Prepare a composition using Formulation 15 as an example. Dissolve 71.6 mg of disodium hydrogen phosphate dodecahydrate (buffer salt) and 280 mg of propylene glycol (for injection) (stabilizer) in purified water. Add 400 mg of the compound of Formula I. Simultaneously add 0.1 M sodium hydroxide solution (pH adjuster) and stir until the ingredients are dissolved. Adjust the pH to the target pH of 7.4 with 0.1 M hydrochloric acid or 0.1 M sodium hydroxide solution. Finally, dilute to 20 mL with purified water. The remaining formulations follow this preparation method.

[0140] Example 3: Detection of polymer impurities in a GLP-1 and GIP dual receptor agonist pharmaceutical composition

[0141] 1. Multimer Detection Method

[0142] Research content: Interference of blank solution and blank excipients on polymer detection.

[0143] Expected requirements: Blank solution and blank excipients should not interfere with the detection of polymers.

[0144] Test process:

[0145] (1) Blank solution: solvent.

[0146] (2) Blank excipient solution: Take blank excipient and obtain.

[0147] (3) System suitability solution: Take approximately 10 mg of the reference compound of Formula I, accurately weigh it, place it in a vial, add 5 ml of solvent and dissolve it by ultrasonication. Place the solution at 60°C for 4 hours.

[0148] (4) Test solution: Take a GLP-1 and GIP dual receptor agonist pharmaceutical composition (injection of the compound of formula I) to obtain.

[0149] Accurately measure 20 μL of system suitability solution and 2 μL of blank solution, blank excipient solution, and test solution and inject them into the liquid chromatograph to record the chromatogram.

[0150] Test results:

[0151] The blank solution and blank excipients did not interfere with the detection of the polymer. In the system suitability solution chromatogram, the polymer and the compound of formula I eluted in sequence. Specific results are shown in Table 11 and Figure 1.

[0152] Table 11 Separation of polymers and this product

[0153] 2. Detection of polymeric impurities in GLP-1 and GIP dual receptor agonist pharmaceutical compositions

[0154] The compound of formula I is a chemically synthesized polypeptide drug, and its preparation may aggregate to form multimers during production and storage. Multimers were detected by SEC.

[0155] Prescription 15 was tested for polymers to investigate the polymer content under high temperature and light conditions. The polymer limit was tentatively set at 2.0%. Specific data are shown in Table 12 and Figure 2.

[0156] Table 12 Multimer detection results of the compound of formula I injection

[0157] Surprisingly, the sample was placed under the proposed storage conditions (2-8°C) for one month without any change in the polymer content. 2-8°C is the storage condition that is expected to be reflected in the instructions for the drug after it is launched on the market. This indicates that the formulation designed in this disclosure solves the technical problem of easy polymerization of polypeptide drugs and can ensure product stability after the drug is launched on the market. Moreover, even under more stringent storage conditions, when stored at 25°C and 30°C for 30 days respectively, the polymer content increased slightly but the content was still within the limit; when placed at 2-8°C, under a total illumination of not less than 1.2×10 6 lux·hr, near-ultraviolet lamp energy not less than 200W·hr / m 2 Under illumination, the polymer content of the unpackaged samples increased but remained within the limit, while the polymer content of the packaged samples did not change significantly.

[0158] In summary, the composition of this product is stable under appropriate storage conditions, and the polymer content is within the limit.

Claims

1. A pharmaceutical composition comprising a GLP-1 and GIP dual receptor agonist, a stabilizer, and a buffer salt; the GLP-1 and GIP dual receptor agonist is a compound of Formula I or a pharmaceutically acceptable salt, ester, solvate, optical isomer, tautomer, isotope-labeled, or prodrug thereof:

2. The pharmaceutical composition according to claim 1, characterized in that The pharmaceutical composition is a liquid preparation; Preferably, the pharmaceutical composition is an injection.

3. The pharmaceutical composition according to claim 2, characterized in that The concentration of the GLP-1 and GIP dual receptor agonist is 2-36 mg / mL.

4. The pharmaceutical composition according to any one of claims 1 to 3, characterized in that The stabilizer is a polyol; Preferably, the stabilizer is propylene glycol, mannitol or glycerol; More preferably, the stabilizer is propylene glycol.

5. The pharmaceutical composition according to any one of claims 2 to 4, characterized in that The concentration of the stabilizer in the pharmaceutical composition is 10-20 mg / mL.

6. The pharmaceutical composition according to any one of claims 1 to 5, characterized in that The buffer salt is selected from hydrogen phosphate, hydrogen phosphate hydrate, citrate or citrate hydrate; Preferably, the buffer salt is disodium hydrogen phosphate dodecahydrate or sodium citrate dihydrate; More preferably, the buffer salt is disodium hydrogen phosphate dodecahydrate.

7. The pharmaceutical composition according to any one of claims 2 to 6, characterized in that The concentration of the buffer salt in the pharmaceutical composition is 7-23 mM.

8. The pharmaceutical composition according to any one of claims 1 to 7, characterized in that The pH value of the pharmaceutical composition is 6.5 to 8.5; Preferably, the pH value of the pharmaceutical composition is 7.0 to 8.4; More preferably, the pH value of the pharmaceutical composition is 7.2 to 8.2; More preferably, the pH value of the pharmaceutical composition is 7.2-7.

6.

9. The pharmaceutical composition according to any one of claims 1 to 8, characterized in that The pharmaceutical composition does not contain a bacteriostatic agent.

10. A pharmaceutical composition comprising a GLP-1 and GIP dual receptor agonist represented by Formula I, a stabilizer, and a buffer salt, wherein the stabilizer is propylene glycol, the buffer salt is disodium hydrogen phosphate dodecahydrate, and the pH value of the pharmaceutical composition is 7.0 to 8.4; and in the pharmaceutical composition, the concentration of the GLP-1 and GIP dual receptor agonist represented by Formula I is 5 to 30 mg / mL, the concentration of the propylene glycol is 10 to 20 mg / mL, and the concentration of the disodium hydrogen phosphate dodecahydrate is 7 to 23 mM. The pharmaceutical composition is an injection.

11. The pharmaceutical composition according to claim 10, characterized in that The pH value of the pharmaceutical composition is 7.2-8.2, and the concentration of disodium hydrogen phosphate dodecahydrate in the pharmaceutical composition is 10-20 mM.

12. The pharmaceutical composition according to claim 10 or 11, characterized in that The pH value of the pharmaceutical composition is 7.2-7.6; in the pharmaceutical composition, the concentration of the GLP-1 and GIP dual receptor agonist represented by Formula I is 5-25 mg / mL, the concentration of the propylene glycol is 14 mg / mL, and the concentration of the sodium hydrogen phosphate dodecahydrate is 10 mM.

13. The pharmaceutical composition according to any one of claims 10 to 12, characterized in that The pharmaceutical composition further comprises a pH adjuster and water; the pH adjuster is hydrochloric acid and / or sodium hydroxide.

14. A method for preparing the pharmaceutical composition according to any one of claims 1 to 13, comprising the steps of: preparing a solution with a stabilizer, a buffer salt and a GLP-1 and GIP dual receptor agonist, and adjusting the pH of the solution to a target value.

15. Use of the pharmaceutical composition according to any one of claims 1 to 13 in the preparation of a medicament for preventing and / or treating diseases related to metabolic disorders; Preferably, the metabolic disorder-related disease is diabetes, diabetic complications, obesity or obesity complications.